Clinical trials: Ischemia, Brain
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Intracranial Aneurysm, Brain Arterial Disease
Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform
BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices.
- Conditions
- Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases
- Trial name
- EVIDENCE (NCT04927156)
- Testing
- BALT medical devices
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 10,000 people
- Sponsor
- Balt Extrusion
Stroke, Acute Ischemic
COlombia DAISe FEasibility Exercise
This study is to assess initial safety and performance data of the DAISe Thrombectomy Device for removal of thrombus during an acute ischemic stroke.
- Trial name
- COFEE (NCT05631483)
- Testing
- DAISe
- Where
- Colombia
- Volunteers
- 2 people
- Sponsor
- MIVI Neuroscience, Inc.
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Post-Cardiac Arrest Syndrome
Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature…
- Trial name
- XePOHCAS (NCT03176186)
- Testing
- Xenon
- Where
- 10 sites in United States, Denmark
- Volunteers
- 1,436 people
- Sponsor
- Invero Pharma, Inc.
Acute Ischemic Stroke
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR Study
A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
- Trial name
- NCT04514562
- Testing
- NeVa Stent Retrievers
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vesalio
Suspected Arrhythmia, Palpitations
This Exploratory Medical Device Study Evaluated the Arrhythmia Diagnostic Yield of MEMO Patch V2, a Wearable Patch-type Electrocardiographic Monitor, in Adults With Suspected Arrhythmia Who Presented With Symptoms Such as Palpitations or Dizziness, or Who Had Cryptogenic Ischemic Stroke or Transient
This exploratory medical device study evaluated the arrhythmia diagnostic yield of MEMO Patch V2, a wearable patch-type electrocardiographic monitor, in adults with suspected arrhythmia who presented with symptoms such as…
- Conditions
- Suspected Arrhythmia, Palpitations, Dizziness, Cryptogenic Ischemic Stroke
- Trial name
- NCT07722026
- Testing
- MEMO Patch V2, 24-Hour Holter Monitor
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- HUINNO Co., Ltd
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Atrial Fibrillation
Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
This study will characterize patients with ischemic stroke, a condition which occurs when a vessel supplying blood to the brain is obstructed, and a subpopulation of patients with irregular and often rapid heart rate (atrial…
- Trial name
- BEST-AF (NCT04099238)
- Testing
- Oral anticoagulant
- Where
- United Kingdom
- Volunteers
- 3,739 people
- Sponsor
- Bayer
Brain Diseases, Vertebral Artery Thrombosis
A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX
Aprospective, multicentre, single-arm clinical trial in which approximately 36 subjects would be enrolled using the Bridge 4.5 mm and 5.0 mm stent in accordance with the inclusion and exclusion criteria in this protocol.
- Conditions
- Brain Diseases, Vertebral Artery Thrombosis, Vertebral Artery Stenosis
- Trial name
- NCT06186024
- Testing
- Bridge
- Where
- China
- Volunteers
- 36 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Quadriplegia, Amputations
A Study on the Safety and Functionality of the Implantable Wireless Brain-Computer Interfaces for Motor Rehabilitation
The objective of this study is to evaluate the safety and efficacy of minimally invasive, wireless brain-machine interface system (WRS) in patients with paralysis (resulting from spinal cord injuries, brainstem strokes…
- Conditions
- Quadriplegia, Amputations, Spinal Cord Injuries (SCI), Brainstem Stroke
- Trial name
- STAIR (NCT06944834)
- Testing
- Implant
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai StairMed Technology Co., Ltd.
Stroke, Acute
Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements
The primary objectives of this study is to evaluate the efficacy of HLCM051 on functional outcome in subjects with acute ischemic stroke and to evaluate the safety of HLCM051 in subjects with acute ischemic stroke.
- Trial name
- TREASURE (NCT02961504)
- Testing
- HLCM051
- Where
- Japan
- Volunteers
- 206 people
- Sponsor
- Healios K.K.
Acute Ischemic Stroke
Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial
This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with…
- Trial name
- NCT06447415
- Testing
- HRS-7450, 0.9% sodium chloride injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
This study is designed to determine the safety and efficacy of SHPL-49 intravenous infusion for 7 consecutive days in the treatment of acute ischemic stroke subjects.
- Trial name
- NCT06202378
- Testing
- 3 ampoules of SHPL-49 Injection, 6 ampoules of SHPL-49 Injection, 0.9% Sodium Chloride Injection
- Where
- 16 sites in China
- Volunteers
- 270 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Stroke, Ischemic
CASTRO1 - Study on CRP Apheresis After Ischemic Stroke
CASTRO1 is a study to investigate the reduction of C-reactive protein (CRP) by therapeutic apheresis (CRP-apheresis) in patients after primary treatment of ischemic stroke.
- Trial name
- CASTRO1 (NCT04417231)
- Testing
- CRP apheresis
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Pentracor GmbH
Stroke
Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke
The main objective of this study is to assess the safety and effectiveness of the ReVive SE (Self- Expanding) Neurothrombectomy Device in subjects requiring mechanical thrombectomy when used according to its Instruction for use…
- Trial name
- Re-ACT (NCT02169492)
- Where
- 8 sites in France
- Volunteers
- 103 people
- Sponsor
- Codman & Shurtleff
Cerebrovascular Stroke
BOBBY™ Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke
Evaluation of the safety and performance of the BOBBY™ Balloon Guide Catheter (BGC) in patients with an acute ischemic stroke treatment, a sudden reduction or termination of the blood circulation of the brain, caused by a clot.
- Trial name
- STRAIT (NCT05361187)
- Testing
- BOBBY™ Balloon Guide Catheter intended for use in neurovascular procedures, performing or as an adjunctive device
- Where
- 9 sites in Germany, Switzerland
- Volunteers
- 171 people
- Sponsor
- Microvention-Terumo, Inc.
Acute Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24A (NCT03767192)
- Testing
- Active Stimulation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 327 people
- Sponsor
- BrainsGate
Acute Ischemic Stroke
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
- Trial name
- NCT04091945
- Testing
- LT3001 Drug Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 24 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.